Skip to main content

Table 2 Exposure to angiotensin II receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors and their relative risk for acute pancreatitis estimated by odds ratio (OR) with 95% confidence intervals (CI)

From: Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden

Exposure

Controls

Cases

Model 1a

Model 2b

Model 3c

N (%)

N (%)

OR 95% CI

OR 95% CI

OR 95% CI

Total

61,637 (100)

6,161 (100)

   

ARB

     

  Never use

56,542 (92)

5,571 (90)

1 (reference)

1 (reference)

1 (reference)

  Current use

4,715 (8)

548 (9)

1 · 18 (1 · 08–1 · 30)

0 · 82 (0 · 74–0 · 90)

0 · 77 (0 · 69–0 · 86)

  Past use

380 (1)

42 (1)

1 · 13 (0 · 82–1 · 55)

0 · 77 (0 · 74–0 · 90)

0 · 70 (0 · 49–1 · 01)

ACE-inhibitors

     

  Never use

55,073 (89)

5,080 (82)

1 (reference)

1 (reference)

1 (reference)

  Current use

6,067 (10)

987 (16)

1 · 82 (1 · 69–1 · 96)

1 · 16 (1 · 07–1 · 26)

1 · 11 (1 · 01–1 · 21)

  Past use

497 (1)

94 (2)

2 · 11 (1 · 69–2 · 63)

1 · 37 (1 · 09–1 · 72)

1 · 24 (0 · 95–1 · 60)

  1. aAdjusting for sex, age and calendar year. bAs Model 1 + presence of cardiovascular disorder
  2. cAdjusting for sex, age, calendar year, education, alcohol related disease, gallstone disease, chronic obstructive pulmonary disease, diabetes, cardiovascular disorder, and number of distinct medications, Angiotensin-converting enzyme (ACE)-inhibitors and ARB